Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

CURB-65, PSI, and APACHE II to assess mortality risk in patients with severe sepsis and community acquired pneumonia in PROWESS.

Richards G, Levy H, Laterre PF, Feldman C, Woodward B, Bates BM, Qualy RL.

J Intensive Care Med. 2011 Jan-Feb;26(1):34-40.

PMID:
21341394
2.

Static and dynamic assessment of biomarkers in surgical patients with severe sepsis.

Lowry SF, Awad S, Ford H, Cheadle W, Williams MD, Qualy RL, McCollam JS, Bates BM, Fry DE; PROWESS Surgical Evaluation Committee.

Surg Infect (Larchmt). 2004 Fall;5(3):261-8.

PMID:
15684797
3.

Safety of drotrecogin alfa (activated) in surgical patients with severe sepsis.

Fry DE, Beilman G, Johnson S, Williams MD, Rodman G, Booth FV, Bates BM, McCollam JS, Lowry SF; PROWESS Surgical Evaluation Committee.

Surg Infect (Larchmt). 2004 Fall;5(3):253-9.

PMID:
15684796
4.

Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis.

Barie PS, Williams MD, McCollam JS, Bates BM, Qualy RL, Lowry SF, Fry DE; PROWESS Surgical Evaluation Committee.

Am J Surg. 2004 Sep;188(3):212-20.

PMID:
15450822
5.

Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.

Barton P, Kalil AC, Nadel S, Goldstein B, Okhuysen-Cawley R, Brilli RJ, Takano JS, Martin LD, Quint P, Yeh TS, Dalton HJ, Gessouron MR, Brown KE, Betts H, Levin M, Macias WL, Small DS, Wyss VL, Bates BM, Utterback BG, Giroir BP.

Pediatrics. 2004 Jan;113(1 Pt 1):7-17.

PMID:
14702440
6.

The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results.

Dhainaut JF, Laterre PF, LaRosa SP, Levy H, Garber GE, Heiselman D, Kinasewitz GT, Light RB, Morris P, Schein R, Sollet JP, Bates BM, Utterback BG, Maki D.

Crit Care Med. 2003 Sep;31(9):2291-301.

PMID:
14501959

Supplemental Content

Loading ...
Support Center